|
|
|
NAFLD
https://www.ncbi.nlm.nih.gov/pubmed/28230607
Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R.
J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):413-417.
Abstract
OBJECTIVES:
This study aims to evaluate the effects of some probiotics on sonographic and biochemical nonalcoholic fatty liver disease(NAFLD).
METHODS:
This randomized triple-blind trial was conducted among 64 obese children with sonographic NAFLD. They were randomly allocated to receive probiotic capsule (containing Lactobacillus acidophilus ATCC B3208, 3 × 10 colony forming units [CFU]; Bifidobacterium lactis DSMZ 32269, 6 × 10 CFU; Bifidobacterium bifidum ATCC SD6576, 2 × 10 CFU; Lactobacillus rhamnosus DSMZ 21690, 2 × 10 CFU) or placebo for 12 weeks.
RESULTS:
https://www.ncbi.nlm.nih.gov/pubmed/31101468 NAFLD
Rev Gastroenterol Mex. 2019 May 14. pii: S0375-0906(19)30019-9. doi: 10.1016/j.rgmx.2019.02.001. [Epub ahead of print]
Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: A scoping review.
[Article in English, Spanish]
Caro-Sabido EA1, Larrosa-Haro A2.
Abstract
AIM:
To identify and discuss the efficacy of dietary interventions, antioxidant supplementation, physical activity, and nutritional and psychologic counseling in the treatment of children and adolescents with non alcoholic fatty liver disease associated with obesity.
MATERIALS AND METHODS:
http://www.ncbi.nlm.nih.gov/pubmed/26043290
Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015 Jul;27(7):840-5.
Abstract
OBJECTIVE:
Recent studies have suggested that endotoxin-induced cytokines play an important role in nonalcoholic fatty liver disease (NAFLD). Rifaximin is a nonabsorbable antibiotic that might act on Gram-negative bacteria, thereby inhibiting endotoxin proinflammatory cytokine production in patients with NAFLD. Our aim was to investigate the efficacy of rifaximin on NAFLD.
METHODS:
https://www.ncbi.nlm.nih.gov/pubmed/28556786 NAFLD
Giorgio V1, Mosca A, Alterio A, Alisi A, Grieco A, Nobili V, Miele L. J Pediatr Gastroenterol Nutr. 2017 Apr 27. doi: 10.1097/MPG.0000000000001614. [Epub ahead of print]
Abstract
OBJECTIVES:
Hemoglobin (Hb) and red blood cell distribution width (RDW) have been reported to be a risk marker of metabolic syndrome (MS) and nonalcoholic fatty liver disease (NAFLD). No study exists on pediatric populations. We aimed to determine the association between hematological parameters, and the severity of disease in children with biopsy proven NAFLD.
METHODS:
https://pubmed.ncbi.nlm.nih.gov/32814993/ NAFLD
Curr Gastroenterol Rep. 2020 Aug 19;22(10):52.
doi: 10.1007/s11894-020-00786-y.
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease
Chuan-Hao Lin 1, Rohit Kohli 2
Abstract
Purpose of review: Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children. In this article, we review recent developments in the screening, diagnosis, and treatment of pediatric NAFLD.
https://pubmed.ncbi.nlm.nih.gov/35581572/ NAFLD
BMC Pediatr. 2022 May 17;22(1):286.
doi: 10.1186/s12887-022-03351-w.
Epidemiology and lifestyle survey of non-alcoholic fatty liver disease in school-age children and adolescents in Shenyang, Liaoning
Guan Lin # 1, Zhang Xinhe # 1, Tian Haoyu 2, Jin Xing 1, Li Dan 1, Wang Ningning 1, Sun Jing 1, Wang Xue 1, Zeng Zilu 1, Li Yiling 3
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is diagnosed increasingly in children and adolescents. We aimed to investigate the prevalence and related influencing factors of NAFLD in school-aged children and adolescents in Shenyang, Liaoning Province. Furthermore, we analyzed the relationship between lifestyle and fatty liver.
https://pubmed.ncbi.nlm.nih.gov/34690666/ NAFLD
Meta-Analysis
Int J Public Health. 2021 Oct 6;66:1604371.
doi: 10.3389/ijph.2021.1604371.eCollection 2021.
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis
Jiaye Liu 1 2, Chunyang Mu 3, Kewei Li 4, Han Luo 1 2, Yong Liu 5, Zhihui Li 1 2
Abstract
https://pubmed.ncbi.nlm.nih.gov/33346578/ NAFLD
J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print. doi: 10.1097/MPG.0000000000003023. Online ahead of print.
Evaluation of Non-Alcoholic Fatty Liver Disease in Pediatric Patients with Inflammatory Bowel Disease
Mallory E Cohen 1 , Parakkal Deepak, Geetika Khanna, Charles M Samson
Abstract
https://pubmed.ncbi.nlm.nih.gov/35899429/ NAFLD
Acta Paediatr. 2022 Jul 28.
doi: 10.1111/apa.16502. Online ahead of print
Evaluation of the feasibility of screening for paediatric non-alcoholic fatty liver disease
Laura Draijer 1 2 3, Maaike Voorhoeve 1, Amsterdam Paediatric Obesity Collaboration; Marc Benninga 1, Bart Koot 1
Collaborators, Affiliations expand
PMID: 35899429
DOI: 10.1111/apa.16502
Abstract
Aim: To evaluate the feasibility of screening for non-alcoholic fatty liver disease (NAFLD) in clinical practice and the acceptance of a screening strategy, and to identify factors that determine compliance.
https://pubmed.ncbi.nlm.nih.gov/32963496/ NAFLD
Mediators Inflamm. 2020 Sep 10;2020:8327945.
Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease
Joanna B Trojanek 1, Jacek Michałkiewicz 1 2, Renata Grzywa-Czuba 1, Wojciech Jańczyk 3, Lidia Gackowska 2, Izabela Kubiszewska 2, Anna Helmin-Basa 2, Aldona Wierzbicka-Rucińska 4, Mieczysław Szalecki 5 6, Piotr Socha 3
PMID: 32963496
Abstract
SMS requests to
9224791366
Ask The Expert
Pediatric Liver Specialists in India
Centres offering Genetic Testing for Pediatric Liver Diseases
Financial Aid Offered by Trusts
